Utility of Self-Administered Questionnaires for Identifying Individuals at Risk of COPD in Japan: The OCEAN (Okinawa COPD casE finding AssessmeNt) Study.


Journal

International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481

Informations de publication

Date de publication:
2021
Historique:
received: 21 01 2021
accepted: 20 05 2021
entrez: 25 6 2021
pubmed: 26 6 2021
medline: 12 8 2021
Statut: epublish

Résumé

A considerable proportion of patients with chronic obstructive pulmonary disease (COPD) remain undiagnosed and untreated even though they may have a burden of respiratory symptoms that impact quality of life. The OCEAN study assessed the ability of screening questionnaires to identify individuals with, or at risk of, COPD by comparing questionnaire outcomes with spirometric measures of lung function. This observational study included participants ≥40 years of age presenting for their annual health examination at a single medical center in Okinawa, Japan. Participants completed COPD screening questionnaires (CAPTURE and COPD-Q), the Chronic Airways Assessment Test (CAAT), and general demographic and health-related questionnaires. The performance characteristics of CAPTURE and COPD-Q were compared with spirometry-based airflow limitation by calculating the area under the receiver operating characteristic (ROC-AUC) curve. A total of 2518 participants were included in the study; 79% of whom were <60 years of age (mean 52.0 years). A total of 52 (2.1%) participants had airflow limitation defined as forced expiratory volume in 1 second (FEV This study demonstrated that CAPTURE and COPD-Q appear to be effective screening tools for identifying symptomatic individuals with undiagnosed, or at risk of developing COPD in adults ≥40 years of age in Okinawa. Furthermore, early diagnosis and management of PRISm is important to improve future outcomes and the societal burden of disease.

Identifiants

pubmed: 34168439
doi: 10.2147/COPD.S302259
pii: 302259
pmc: PMC8216667
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1771-1782

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 Tamaki et al.

Déclaration de conflit d'intérêts

Kentaro Tamaki, Eishin Sakihara, Hiroaki Miyata, and Norimichi Hirahara belong to the association/institution that received funding for this study from GSK. Takeo Ishii, Shoko Akiyama, Toshihiko Kaise, Masayuki Katsumata and Ryosuke Tawara are employees of GSK and hold shares in GSK. Mei Haruya, Oksana Kirichek and Edgar P. Simard are former employees of GSK. Bruce E. Miller and Ruth Tal-Singer are former employees of GSK and hold shares in GSK. Ruth Tal-Singer reports personal fees from Ena Respiratory, Immunomet, Vocalis Health, and Teva. The authors report no other conflicts of interest in this work.

Références

PLoS One. 2016 Apr 19;11(4):e0152618
pubmed: 27092775
Eur Respir J. 2014 Oct;44(4):873-84
pubmed: 24993906
PLoS One. 2013 Dec 13;8(12):e83725
pubmed: 24349548
Respirology. 2020 Apr;25(4):401-409
pubmed: 31339206
J Clin Epidemiol. 2016 May;73:112-8
pubmed: 26970039
Eur Respir J. 2008 Feb;31(2):298-303
pubmed: 17959636
Respir Res. 2011 Oct 12;12:136
pubmed: 21991942
Respir Care. 2018 Feb;63(2):242-252
pubmed: 29367384
Int J Chron Obstruct Pulmon Dis. 2020 Feb 26;15:439-460
pubmed: 32161455
Lancet Respir Med. 2017 Sep;5(9):691-706
pubmed: 28822787
NPJ Prim Care Respir Med. 2017 Dec;27(1):4
pubmed: 28127061
Eur Respir J. 2020 Jan 2;55(1):
pubmed: 31601717
Prim Care Respir J. 2011 Mar;20(1):15-22
pubmed: 20871945
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582
pubmed: 28128970
Eur Respir J. 2009 Sep;34(3):648-54
pubmed: 19720809
Am J Respir Crit Care Med. 2021 Feb 15;203(4):414-423
pubmed: 33211970
Int J Chron Obstruct Pulmon Dis. 2018 Oct 26;13:3459-3471
pubmed: 30464435
Lancet. 2007 Sep 1;370(9589):741-50
pubmed: 17765523
Respir Investig. 2019 May;57(3):220-226
pubmed: 30773474
Am J Respir Crit Care Med. 2018 Dec 1;198(11):1397-1405
pubmed: 29874098
Int J Chron Obstruct Pulmon Dis. 2018 Aug 28;13:2629-2641
pubmed: 30214181
Thorax. 2014 May;69(5):491-4
pubmed: 24029743
Am J Respir Crit Care Med. 2017 Mar 15;195(6):748-756
pubmed: 27783539
Eur Respir Rev. 2017 Mar 15;26(143):
pubmed: 28298389
ERJ Open Res. 2019 Feb 01;5(1):
pubmed: 30723727
Respir Investig. 2012 Jun;50(2):34-9
pubmed: 22749248
Respir Med. 2018 Jul;140:127-131
pubmed: 29957274
Chronic Obstr Pulm Dis. 2020 Oct;7(4):346-361
pubmed: 32877963
Eur Respir J. 2012 May;39(5):1230-40
pubmed: 22088970
Chronic Obstr Pulm Dis. 2019 Nov;6(5):438-443
pubmed: 31710800
Int J Chron Obstruct Pulmon Dis. 2017 May 15;12:1469-1481
pubmed: 28553099
Respir Res. 2014 Aug 06;15:89
pubmed: 25096860
Value Health. 2019 May;22(5):537-544
pubmed: 31104731
Respir Res. 2014 Feb 06;15:13
pubmed: 24502760
Int J Chron Obstruct Pulmon Dis. 2016 Apr 22;11:873-80
pubmed: 27217740
Int J Chron Obstruct Pulmon Dis. 2014 Jun 06;9:597-611
pubmed: 24944511
N Engl J Med. 2016 May 12;374(19):1811-21
pubmed: 27168432
Eur Respir J. 2020 Jan 2;55(1):
pubmed: 31896682
Eur Respir J. 2014 May;43(5):1289-97
pubmed: 24232696
Int J Chron Obstruct Pulmon Dis. 2016 Mar 01;11:431-7
pubmed: 27042035
Int J Chron Obstruct Pulmon Dis. 2020 Sep 04;15:2081-2090
pubmed: 32943861
PLoS Med. 2006 Nov;3(11):e442
pubmed: 17132052
Respirology. 2004 Nov;9(4):458-65
pubmed: 15612956

Auteurs

Kentaro Tamaki (K)

Department of Breast Surgery, Nahanishi Clinic, Okinawa, Japan.

Eishin Sakihara (E)

Lifestyle Related Disease Medical Center, Naha Medical Association, Okinawa, Japan.

Hiroaki Miyata (H)

Health Policy and Management, School of Medicine, Keio University, Tokyo, Japan.

Norimichi Hirahara (N)

Health Policy and Management, School of Medicine, Keio University, Tokyo, Japan.

Oksana Kirichek (O)

Value Evidence and Outcomes, GSK, Stockley Park, UK.

Ryosuke Tawara (R)

Japan Development, GSK, Tokyo, Japan.

Shoko Akiyama (S)

Japan Development, GSK, Tokyo, Japan.

Masayuki Katsumata (M)

Japan Development, GSK, Tokyo, Japan.

Mei Haruya (M)

Government Affairs and Market Access, GSK, Tokyo, Japan.

Takeo Ishii (T)

Medical Japan, GSK, Tokyo, Japan.

Edgar P Simard (EP)

Value Evidence and Outcomes, GSK, Collegeville, PA, USA.

Bruce E Miller (BE)

Value Evidence and Outcomes, GSK, Collegeville, PA, USA.

Ruth Tal-Singer (R)

Value Evidence and Outcomes, GSK, Collegeville, PA, USA.

Toshihiko Kaise (T)

Japan Development, GSK, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH